{"id":84015,"date":"2017-09-07T21:53:10","date_gmt":"2017-09-07T21:53:10","guid":{"rendered":"http:\/\/healthmedicinet.com\/news\/no-difference-in-toxicity-for-6-2-fraction-hdr-in-prostate-cancer\/"},"modified":"2017-09-07T21:53:10","modified_gmt":"2017-09-07T21:53:10","slug":"no-difference-in-toxicity-for-6-2-fraction-hdr-in-prostate-cancer","status":"publish","type":"post","link":"http:\/\/healthmedicinet.com\/news\/no-difference-in-toxicity-for-6-2-fraction-hdr-in-prostate-cancer\/","title":{"rendered":"No difference in toxicity for 6-, 2-fraction HDR in prostate cancer"},"content":{"rendered":"<article>\n<figure class=\"image-block\">\n<p>                <\/a><\/p>\n<\/figure>\n<p>(HealthDay)\u2014For men with prostate cancer there is no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, according to a study published online Aug. 29 in the <i>Journal of Medical Imaging and Radiation Oncology<\/i>.\n                                <\/p>\n<p>Omar Ragab, M.D., from the University of Southern California in Los Angeles, and colleagues conducted a retrospective study involving 116 men with prostate cancer<\/a> treated with HDR monotherapy from 2010 to 2015. Eighty-one and 35 men had 7.25 Gy \u00d7 6-fractions and 13.5 Gy \u00d7 2-fractions, respectively. Patients underwent two computed tomography-planned implants spaced one to two weeks apart. Pre-treatment and at three, six, and 12 months post-implantation, patient baseline characteristics, International Prostate Symptom Scores (IPSS), and Sexual Health Inventory for Men (SHIM) scores were collected.<\/p>\n<p>The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores. Men treated with 6-fractions had a steeper decline in SHIM scores at one to six months, but it resolved at seven to 12 months. Worse short-term acute urinary toxicity was seen with pre-treatment alpha-blocker use. There was a correlation for worsened SHIM score with increasing age, diabetes mellitus, and androgen-deprivation therapy. Prostate V150 dose and bladder wall dose correlated with increased IPSS score<\/a> in a dosimetric analysis of outcomes.<\/p>\n<p>&#8220;Future research should continue to standardize and validate dose constraints for prostate<\/a> HDR monotherapy patients,&#8221; the authors write.\n                                                                <\/p>\n<p class=\"news-relevant\">\n                                        <img loading=\"lazy\" decoding=\"async\" class=\"toolsicon ic-rel\" src=\"https:\/\/b98584f181.site.internapcdn.net\/tmpl\/v5\/img\/1x1.gif\" width=\"14\" height=\"16\" alt=\"\" \/><\/a><br \/>\n                                        <b>Explore further:<\/b><br \/>\n                                        Study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate cancer<\/a>\n                                    <\/p>\n<p>\n                                        <b>More information:<\/b><br \/>\n                                        Abstract<\/a><br \/>Full Text (subscription or payment may be required)<\/a><br \/>\n                                        <\/p>\n<footer class=\"post-floor clearfix\">\n                                    <!-- rating --><\/p>\n<p>                                                <img loading=\"lazy\" decoding=\"async\" class=\"toolsicon icon-fbck\" src=\"https:\/\/b98584f181.site.internapcdn.net\/tmpl\/v5\/img\/1x1.gif\" width=\"12\" height=\"12\" alt=\"feedback\" \/><br \/>\n                                                feedback to editors<br \/>\n                                            <\/a><\/p>\n<section class=\"copyright\">\n<p>\n\t\t\t\t\t    <img loading=\"lazy\" decoding=\"async\" alt=\"Healthday\" src=\"https:\/\/b98584f181.site.internapcdn.net\/tmpl\/v5\/img\/content\/HEALTHDAY_Web_small2.jpg\" width=\"80\" height=\"24\" \/>                                            Copyright \u00a9 2017 HealthDay<\/a>. All rights reserved.<br \/>\n\t\t\t\t\t<\/p>\n<\/section>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>(HealthDay)\u2014For men with prostate cancer there is no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, according to a study published online Aug. 29 in the Journal of Medical Imaging and Radiation Oncology. Omar Ragab, M.D., from the University of Southern California in Los Angeles, and colleagues conducted [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-84015","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/84015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/comments?post=84015"}],"version-history":[{"count":0,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/84015\/revisions"}],"wp:attachment":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/media?parent=84015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/categories?post=84015"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/tags?post=84015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}